AC Immune Selects Alzheimer's Drug Candidates
Posted on: Thursday, 9 March 2006, 21:00 CST
Swiss biotech company AC Immune has identified two lead drug candidates for clinical development as treatments for Alzheimer's disease.
The company has identified a vaccine as well as a passive immunotherapy with a selected monoclonal antibody which was highly active in animal models for Alzheimer's disease. Both treatments significantly improved memory capacity in animal models.
Both therapies build on antibodies generated by AC Immune's SupraAntigen Technology. They are conformation-specific and have induced the anticipated transition from the insoluble to the soluble form of the plaque-forming beta amyloid protein. This event directly correlated with the observed memory improvement.
"The highly significant functional improvement of memory function in Alzheimer's disease animal models gives us a solid basis for the clinical development program in front of us," said Andrea Pfeifer, CEO of AC Immune.
Source: Datamonitor
Related Articles
- Does Diabetes Speed Up Memory Loss In Alzheimer's Disease?
- Scientists Remove Amyloid Plaques From Brains Of Live Animals With Alzheimer's Disease
- Declines In Other Thinking And Learning Skills May Precede Memory Loss In Alzheimer's Disease
- Drug Could Improve The Memory Of Those With Alzheimer’s Disease
- Early Research Suggests Umbilical Cord Blood Cell Therapy May Reduce Progression of Alzheimer's Disease
- Samaritan Pharma: Early Stage Alzheimer's Disease Diagnostic Patent Issued in Australia
- Wine May Help Against Alzheimer's Disease
- Roche and GE Healthcare to Explore Personalized Medicine in Patients With Alzheimer's Disease
- Does Donepezil Treatment Slow the Progression of Hippocampal Atrophy in Patients With Alzheimer's Disease?
- New Treatments for Alzheimer's Disease From Rockefeller Institute
 |
 |
User Comments (0)
RSS Feeds